Improved Strategies for Outpatient Opioid Detoxification

PHASE1CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Opioid Dependence
Interventions
DRUG

oral naltrexone

Following detoxification with buprenorphine (one dy of 8 mg) followed by oral naltrexone (ascending taper to 25 mg), participants will receive Vivitrol injection on Day 8. Behavioral therapy sessions will be offered for five weeks.

DRUG

Buprenorphine

Following detoxification with buprenorphine \[8-mg buprenorphine (Day 1) tapering to 0 mg (Day 7)\] participants will receive Vivitrol injection on Day 15. Behavioral therapy sessions will be offered for five weeks.

DRUG

Vivitrol

dose of long-acting injectable naltrexone (Vivitrol 380 mg i.m. Injection)

Trial Locations (1)

10032

Substance Treatment and Research Service (STARS), Columbia University, New York

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT01377610 - Improved Strategies for Outpatient Opioid Detoxification | Biotech Hunter | Biotech Hunter